1 min read
Add as a preferred source on Google

Aytu BioPharma Agrees to Rosemont Buyout at $2.70 Per Share

A wholly owned Rosemont subsidiary plans to make a cash offer for all of Aytu’s outstanding common shares.

An anonymous hand passes a blank share certificate through a brass slot / TokenPost.ai (mono)
An anonymous hand passes a blank share certificate through a brass slot / TokenPost.ai (mono)

Aytu BioPharma, Inc. has agreed to a cash acquisition by Rosemont Pharmaceuticals at $2.70 per share, with the transaction structured as a tender offer covering the company’s outstanding common stock.

The definitive merger agreement calls for Rosemont to make the offer through a subsidiary it wholly owns. The bid would cover every Aytu common share still outstanding.

The acquisition remains pending. The subsidiary is to begin the tender offer under the agreement.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…